Patients with advanced pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...

A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was ...

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression ...

Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...

Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas (mPDACs), ...

Larynx-preserving treatment strategy for patients with resectable cervical esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium.

BOSTON — Key DNA and chromosomal and immune cell changes in early-stage lung adenocarcinoma show significant associations with outcomes, representing potentially important early predictors to guide ...